Trial Profile

A Phase 1, Placebo-controlled, Randomized, Observer-blind, First-in-human Study to Describe the Safety, Reactogenicity and Immunogenicity of SCB-1019 in Healthy Adults

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 04 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SCB-1019 (Primary)
Indications Respiratory syncytial virus infections
Focus Adverse reactions; First in man
Sponsors Clover Biopharmaceuticals

Most Recent Events

18 Jun 2024 According to a Clover Biopharmaceuticals Media Release, full Phase 1 clinical readout expected by the end of 2024 to support further development and strengthen our potentially differentiated profile for markets globally.
18 Jun 2024 Preliminary results (n=48) presented in a Clover Biopharmaceuticals Media Release.
08 Apr 2024 Results presented in a Clover Biopharmaceuticals Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com